Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice-Reference-Cited by-同舟云学术

Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice

Published:2011-08-01 Issue:8 Volume:121 Page:3100-3108
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:J. Clin. Invest.

Author:

Lesterhuis W. Joost,Punt Cornelis J.A.,Hato Stanleyson V.,Eleveld-Trancikova Dagmar,Jansen Bastiaan J.H.,Nierkens Stefan,Schreibelt Gerty,de Boer Annemiek,Van Herpen Carla M.L.,Kaanders Johannes H.,van Krieken Johan H.J.M.,Adema Gosse J.,Figdor Carl G.,de Vries I. Jolanda M.

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference37 articles.

1. Immunotherapy and chemotherapy — a practical partnership

2. Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T Cells

3. Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent Mechanism

4. Calreticulin exposure dictates the immunogenicity of cancer cell death

Cited by 279 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Left out in the cold: Moving beyond hormonal therapy for the treatment of immunologically cold prostate cancer with CAR T cell immunotherapies;The Journal of Steroid Biochemistry and Molecular Biology;2024-10

2. Genomic correlates of the response to first-line PD-1 blockade plus chemotherapy in patients with advanced non-small-cell lung cancer;Chinese Medical Journal;2024-08-21

3. Immunotherapy for head and neck cancer: Fundamentals and therapeutic development;Auris Nasus Larynx;2024-08

4. Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial;Med;2024-08

5. Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma;Cancer Immunology, Immunotherapy;2024-06-04